2022
Azacitidine maintenance in AML post induction and posttransplant
Bewersdorf JP, Prebet T, Gowda L. Azacitidine maintenance in AML post induction and posttransplant. Current Opinion In Hematology 2022, 29: 84-91. PMID: 35013047, DOI: 10.1097/moh.0000000000000700.Peer-Reviewed Original ResearchMeSH KeywordsAzacitidineHematopoietic Stem Cell TransplantationHumansLeukemia, Myeloid, AcuteRecurrenceRemission InductionConceptsDisease-free survivalPostremission therapyAcute myeloid leukemiaAllo-HCTCC-486Allogeneic hematopoietic cell transplantNonrelapse mortality riskOverall survival benefitHematopoietic cell transplantDuration of remissionSubset of patientsRobust study designsAML trialsAzacitidine maintenanceInduction therapySurvival benefitAML patientsCell transplantDisease relapseRelapse reductionRelapse riskMyeloid leukemiaCommon causeSelect populationMortality riskRisk classification at diagnosis predicts post-HCT outcomes in intermediate-, adverse-risk, and KMT2A-rearranged AML
Menghrajani K, Gomez-Arteaga A, Madero-Marroquin R, Zhang MJ, Bo-Subait K, Sanchez J, Wang HL, Aljurf M, Assal A, Bacher V, Badawy SM, Bejanyan N, Bhatt VR, Bredeson C, Byrne M, Castillo P, Cerny J, Chhabra S, Ciurea SO, DeFilipp Z, Farhadfar N, Gadalla S, Gale RP, Ganguly S, Gowda L, Grunwald M, Hashmi S, Hildebrandt G, Kanakry CG, Kansagra A, Khimani F, Krem M, Lazarus H, Liu H, Martino R, Michelis FV, Nathan S, Nishihori T, Olsson R, Reshef R, Rizzieri D, Rowe JM, Savani BN, Seo S, Sharma A, Solh M, Ustun C, Verdonck LF, Hourigan C, Sandmaier B, Litzow M, Kebriaei P, Weisdorf D, Zhang Y, Tallman MS, Saber W. Risk classification at diagnosis predicts post-HCT outcomes in intermediate-, adverse-risk, and KMT2A-rearranged AML. Blood Advances 2022, 6: 828-847. PMID: 34551064, PMCID: PMC8945306, DOI: 10.1182/bloodadvances.2021004881.Peer-Reviewed Original ResearchMeSH KeywordsHematopoietic Stem Cell TransplantationHumansLeukemia, Myeloid, AcuteRecurrenceRemission InductionConceptsAcute myeloid leukemiaPost-HCT outcomesRisk classificationAdverse-risk acute myeloid leukaemiaAdverse-risk diseaseFirst complete remissionIntermediate-risk diseaseLeukemia-free survivalAdjusted multivariable analysisCell transplantation outcomesRisk of relapseNovel treatment strategiesCIBMTR databaseComplete remissionOverall survivalMultivariable analysisRisk stratificationTransplantation outcomesMyeloid leukemiaTreatment strategiesPatientsFinal analysisAdverse riskKMT2ADisease
2021
Impact of depth of clinical response on outcomes of acute myeloid leukemia patients in first complete remission who undergo allogeneic hematopoietic cell transplantation
Percival ME, Wang HL, Zhang MJ, Saber W, de Lima M, Litzow M, Kebriaei P, Abdel-Azim H, Adekola K, Aljurf M, Bacher U, Badawy SM, Beitinjaneh A, Bejanyan N, Bhatt V, Byrne M, Cahn JY, Castillo P, Chao N, Chhabra S, Copelan E, Cutler C, DeFilipp Z, Dias A, Diaz MA, Estey E, Farhadfar N, Frangoul HA, Freytes CO, Gale RP, Ganguly S, Gowda L, Grunwald M, Hossain N, Kamble RT, Kanakry CG, Kansagra A, Kharfan-Dabaja MA, Krem M, Lazarus HM, Lee JW, Liesveld JL, Lin R, Liu H, McGuirk J, Munker R, Murthy HS, Nathan S, Nishihori T, Olsson RF, Palmisiano N, Passweg JR, Prestidge T, Ringdén O, Rizzieri DA, Rybka WB, Savoie ML, Schultz KR, Seo S, Sharma A, Solh M, Strair R, van der Poel M, Verdonck LF, Yared JA, Weisdorf D, Sandmaier BM. Impact of depth of clinical response on outcomes of acute myeloid leukemia patients in first complete remission who undergo allogeneic hematopoietic cell transplantation. Bone Marrow Transplantation 2021, 56: 2108-2117. PMID: 33864019, PMCID: PMC8425595, DOI: 10.1038/s41409-021-01261-6.Peer-Reviewed Original ResearchMeSH KeywordsHematopoietic Stem Cell TransplantationHumansLeukemia, Myeloid, AcuteNeoplasm, ResidualPrognosisRemission InductionRetrospective StudiesConceptsMeasurable residual diseaseNon-relapse mortalityDisease-free survivalAllogeneic hematopoietic cell transplantationShorter disease-free survivalAcute myeloid leukemia patientsFirst complete remissionComplete remissionHematopoietic cell transplantationMyeloid leukemia patientsOverall survivalClinical responseCell transplantationLeukemia patientsPresence of MRDDetectable measurable residual diseaseHigher non-relapse mortalityIncomplete count recoveryTime of alloHCTTransplant-related factorsShorter overall survivalLikelihood of deathAlloHCT outcomesAdult patientsBaseline characteristics